Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
7 Angebote vergleichen
Preise | März 17 | März 19 | Sep. 19 |
---|---|---|---|
Schnitt | € 35,90 | € 35,74 | € 34,47 |
Nachfrage |
1
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
DE NW
ISBN: 9783330036512 bzw. 3330036516, in Deutsch, neu.
Lieferung aus: Vereinigtes Königreich Großbritannien und Nordirland, Lieferzeit: 11 Tage, zzgl. Versandkosten.
Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud.
Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud.
2
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
DE HC NW
ISBN: 9783330036512 bzw. 3330036516, in Deutsch, Lap Lambert Academic Publishing, gebundenes Buch, neu.
Lieferung aus: Deutschland, Versandkostenfrei innerhalb von Deutschland.
Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud Lieferzeit 1-2 Werktage.
Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud Lieferzeit 1-2 Werktage.
3
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients - Efficacy of Montelukast when added with Corticosteroids on Asthmatic Patients
DE PB NW
ISBN: 9783330036512 bzw. 3330036516, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients: Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud, Englisch, Taschenbuch.
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients: Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud, Englisch, Taschenbuch.
4
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
DE PB NW
ISBN: 3330036516 bzw. 9783330036512, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
5
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
~EN PB NW
ISBN: 3330036516 bzw. 9783330036512, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
6
Efficacy of Montelukast with Corticosteroids on Asthmatic Patients
DE NW
ISBN: 3330036516 bzw. 9783330036512, in Deutsch, neu.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
Efficacy of Montelukast with Corticosteroids on (2017)
DE PB NW
ISBN: 9783330036512 bzw. 3330036516, in Deutsch, Taschenbuch, neu.
Lieferung aus: Deutschland, Next Day, Versandkostenfrei.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…